Lpl Financial LLC Xencor Inc Transaction History

Lpl Financial LLC

  • $218 Billion
  • Q3 2024

A detailed history of Lpl Financial LLC transactions in Xencor Inc stock. As of the latest transaction made, Lpl Financial LLC holds 17,567 shares of XNCR stock, worth $416,864. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,567
Previous 16,395 7.15%
Holding current value
$416,864
Previous $310,000 13.87%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
BUY
$15.7 - $21.65 $18,400 - $25,373
1,172 Added 7.15%
17,567 $353,000
Q2 2024

Aug 07, 2024
BUY
$18.21 - $24.5 $6,100 - $8,207
335 Added 2.09%
16,395 $310,000
Q1 2024

May 10, 2024
BUY
$18.65 - $26.52 $17,437 - $24,796
935 Added 6.18%
16,060 $355,000
Q4 2023

Feb 14, 2024
BUY
$16.53 - $21.42 $10,827 - $14,030
655 Added 4.53%
15,125 $321,000
Q3 2023

Nov 13, 2023
BUY
$20.08 - $25.39 $9,116 - $11,527
454 Added 3.24%
14,470 $291,000
Q2 2023

Jul 31, 2023
BUY
$24.77 - $29.9 $17,710 - $21,378
715 Added 5.38%
14,016 $349,000
Q1 2023

May 10, 2023
BUY
$25.95 - $36.95 $25,119 - $35,767
968 Added 7.85%
13,301 $370,000
Q4 2022

Feb 07, 2023
BUY
$24.79 - $30.86 $3,842 - $4,783
155 Added 1.27%
12,333 $321,000
Q3 2022

Nov 14, 2022
BUY
$24.62 - $32.44 $10,832 - $14,273
440 Added 3.75%
12,178 $316,000
Q2 2022

Aug 12, 2022
BUY
$19.74 - $29.01 $36,400 - $53,494
1,844 Added 18.64%
11,738 $321,000
Q1 2022

May 16, 2022
SELL
$26.68 - $41.63 $880 - $1,373
-33 Reduced 0.33%
9,894 $264,000
Q4 2021

Feb 14, 2022
SELL
$33.67 - $43.44 $3,299 - $4,257
-98 Reduced 0.98%
9,927 $398,000
Q3 2021

Nov 15, 2021
BUY
$30.65 - $35.68 $307,266 - $357,692
10,025 New
10,025 $327,000

Others Institutions Holding XNCR

# of Institutions
216
Shares Held
71.8M
Call Options Held
2.5K
Put Options Held
7.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.42B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Lpl Financial LLC Portfolio

Follow Lpl Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email